Related Experiment Video
Updated: May 17, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma
Nobuyuki Fujiwara1, Hideyoshi Kawasaki, Ryotaro Yabe
1Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Japan.
Abstract:
Lymphoma is one of the most common malignant tumors in canine. Chemotherapy results in a high rate of remission; however, relapse and clinical drug resistance are usually seen within a year. Protein phosphatase 2A (PP2A) acts as a tumor suppressor and plays a critical role in mammalian cell transformation. Increased protein levels of SET, endogenous PP2A inhibitor, have been reported to correlate with poor prognosis in human leukemia. Here, we test the potential therapeutic role for a SET antagonist in canine lymphoma. We observed SET protein levels increased in multiple canine lymphoma cell lines compared with primary peripheral blood cells. A novel SET antagonist OP449 increased PP2A activity and effectively killed SET high-expressing canine lymphoma cells, but not SET low-expressing cells. Caspase-3 activation and enhanced Annexin V positive staining were observed after OP449 treatment, suggesting apoptotic cell death by OP449. Consistent with this, pan-caspase inhibitor Z-VAD-FMK blocked OP449 induced cell death. These data demonstrated the potential therapeutic application of SET antagonists for canine lymphoma.
Insights
A novel drug targeting the SET protein shows promise for treating canine lymphoma. This SET antagonist effectively killed lymphoma cells by inducing apoptosis, offering a potential new therapy for this common canine cancer.
Area of Science:
- Veterinary Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Canine lymphoma is a common malignancy with frequent relapse and drug resistance after chemotherapy.
- Protein phosphatase 2A (PP2A) is a tumor suppressor, and its inhibitor, SET, is linked to poor prognosis in human leukemia.
- Elevated SET protein levels are observed in canine lymphoma cells, suggesting a potential therapeutic target.
Purpose of the Study:
- To investigate the therapeutic potential of a SET antagonist in canine lymphoma.
- To determine if targeting SET can overcome drug resistance in canine lymphoma cells.
Main Methods:
- Assessed SET protein levels in canine lymphoma cell lines and peripheral blood cells.
- Treated SET high-expressing and low-expressing canine lymphoma cells with the SET antagonist OP449.
- Evaluated cell death pathways, including caspase-3 activation and Annexin V staining.
- Utilized a pan-caspase inhibitor (Z-VAD-FMK) to confirm the mechanism of cell death.
Main Results:
- SET protein levels were significantly higher in canine lymphoma cell lines compared to normal cells.
- The SET antagonist OP449 selectively killed SET high-expressing canine lymphoma cells.
- OP449 treatment induced apoptotic cell death, evidenced by caspase-3 activation and Annexin V staining.
- OP449-induced cell death was blocked by the pan-caspase inhibitor Z-VAD-FMK.
Conclusions:
- SET antagonists, such as OP449, demonstrate significant potential as a therapeutic strategy for canine lymphoma.
- Targeting SET effectively induces apoptosis in canine lymphoma cells, offering a novel approach to treatment.
- Further research into SET antagonists could lead to improved outcomes for dogs with lymphoma.
